Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 2/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 4/20 | 0.43 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 5/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.38 |
| ▸ | MAPT | P10636 | 5/20 | 0.38 |
| ▸ | LMNA | P02545 | 4/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.35 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.35 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.35 |
| ▸ | USP2 | O75604 | 1/20 | 0.35 |
| ▸ | IDE | P14735 | 1/20 | 0.35 |
| ▸ | TNNI3 | P19429 | 1/20 | 0.35 |
| ▸ | TNNT2 | P45379 | 1/20 | 0.35 |
| ▸ | TNNC1 | P63316 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12947626 | 1.00 | CYP2C9 (0.47) | CYP2C9NPSR1GLO1ALDH1A1CYP2D6 | |
| SCHEMBL961667 | 1.00 | CYP2C9 (0.47) | CYP2C9NPSR1GLO1ALDH1A1CYP2D6 | |
| SCHEMBL18134660 | 0.88 | CYP2C9 (0.46) | CYP2C9NPSR1GLO1ALDH1A1CYP2D6 | |
| SCHEMBL3594318 | 0.87 | CYP2C9 (0.45) | CYP2C9NPSR1GLO1ALDH1A1CYP2D6 | |
| SCHEMBL21975389 | 0.87 | CYP2C9 (0.49) | CYP2C9NPSR1GLO1ALDH1A1CYP2D6 | |
| SCHEMBL18936322 | 0.87 | CYP2C9 (0.45) | CYP2C9NPSR1GLO1ALDH1A1CYP2D6 | |
| SCHEMBL18134656 | 0.85 | CYP2C9 (0.44) | CYP2C9NPSR1GLO1ALDH1A1CYP2D6 | |
| SCHEMBL1406245 | 0.85 | NPSR1 (0.42) | CYP2C9NPSR1GLO1ALDH1A1CYP2D6 | |
| SCHEMBL18936311 | 0.85 | NPSR1 (0.42) | CYP2C9NPSR1GLO1ALDH1A1CYP2D6 | |
| SCHEMBL1014223 | 0.84 | CYP2C9 (0.49) | CYP2C9NPSR1GLO1ALDH1A1CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 62 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2247577-B2 | METHOD FOR THE REGIOSELECTIVE SYNTHESIS OF 1-ALKYL-3-HALOALKYL-PYRAZOLE-4-CARBOXYLIC ACID DERIVATIVES | BAYER IP GMBH (DE) | 2022-04-27 | — | — | EP | claimed |
| EP-2247577-B1 | METHOD FOR THE REGIOSELECTIVE SYNTHESIS OF 1-ALKYL-3-HALOALKYL-PYRAZOLE-4-CARBOXYLIC ACID DERIVATIVES | BAYER IP GMBH (DE) | 2015-12-23 | — | — | EP | claimed |
| US-8629288-B2 | Method for the regioselective synthesis of 1-alky1-3-haloalkyl-pyrazole-4-carboxylic acid derivatives | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-01-14 | — | — | US | claimed |
| US-20110009642-A1 | Method for the Regioselective Synthesis of 1-Alkyl-3-haloalkyl-pyrazole-4-carboxylic Acid Derivatives | BAYER CROPSCIENCE AG (DE) | 2011-01-13 | — | — | US | claimed |
| EP-2133341-A1 | Method for regioselective synthesis of 1-alkyl-3-haloalkyl-1-pyrazol-4-carbonic acid derivatives | Bayer CropScience AG (DE) | 2009-12-16 | — | — | EP | claimed |
| US-6207828-B1 | REACTING TRIHALOACETYL COMPOUND WITH AN ACETAL IN PRESENCE OF AN ORGANIC ACID | ROLM AND HAAS COMPANY | 2001-03-27 | — | — | US | claimed |
| EP-1000926-A1 | Process for making 2-(trihaloacetyl)-3-(substituted aminos)-2-propenoates | ROHM AND HAAS COMPANY (US) | 2000-05-17 | — | — | EP | claimed |
| US-20250243190-A1 | NEW DEUTERATED RORGAMMA/RORGAMMAT INVERSE AGONISTS | IMMUNIC AG (DE) | 2025-07-31 | — | — | US | disclosed |
| WO-2025105858-A1 | HETEROARYL-DERIVATIVE COMPOUND AND USE THEREOF | (주)신테카바이오 | 2025-05-22 | — | — | WO | disclosed |
| WO-2025105857-A1 | HETEROARYL-DERIVATIVE COMPOUND AND USE THEREOF | (주)신테카바이오 | 2025-05-22 | — | — | WO | disclosed |
| EP-4508049-A1 | DEUTERATED RORGAMMA/RORGAMMAT INVERSE AGONISTS | Immunic AG (DE) | 2025-02-19 | — | — | EP | disclosed |
| WO-2023198873-A1 | DEUTERATED RORGAMMA/RORGAMMAT INVERSE AGONISTS | IMMUNIC AG (DE) | 2023-10-19 | — | — | WO | disclosed |
| EP-4074708-A1 | 1-(4-(ISOXAZOL-5-YL)-1H-PYRAZOL-1-YL)-2-METHYLPROPAN-2-OL DERIVATIVES AND RELATED COMPOUNDS AS IL-7 AND IFN-GAMMA INHIBITORS FOR TREATING AUTOIMMUNE DISEASES AND CHRONIC INFLAMMATION | Immunic AG (DE) | 2022-10-19 | — | — | EP | disclosed |
| US-20040147561-A1 | Pyrid-2-one derivatives and methods of use | SYNGENTA CROP PROTECTION AG (CH) | 2004-07-29 | — | — | US | disclosed |
| WO-2004060890-A1 | 2-OXOPYRIDIN-3-YL THIA (DI) AZOLE DERIVATES FOR USE IN THE TREATMENT OF CELL PROLIFERATION AND APOPTOSIS RELATED DISEASES | AMGEN INC. (US) | 2004-07-22 | — | — | WO | disclosed |
| US-6706911-B1 | REACTING N-SUBSTITUTED 3-AMINOACRYLIC ESTERS WITH HALOALKYLCARBOXYLIC ANHYDRIDES IN PRESENCE OF BASE; PYRAZOLE-4-CARBOXYLIC ACID CHEMICAL INTERMEDIATES; HALOACYLATION | BAYER AKTIENGESELLSCHAFT (DE) | 2004-03-16 | — | — | US | disclosed |
| WO-2003051820-A1 | METHOD FOR PRODUCING 2-HALOGENACYL-3-AMINO-ACRYLIC ACID DERIVATIVES | BAYER CHEMICALS AG (DE) | 2003-06-26 | — | — | WO | disclosed |
| US-6207828-B1 | REACTING TRIHALOACETYL COMPOUND WITH AN ACETAL IN PRESENCE OF AN ORGANIC ACID | ROLM AND HAAS COMPANY | 2001-03-27 | — | — | US | disclosed |
| JP-2000143593-A | PRODUCTION OF 2-(TRIHALOACETYL)-3-(SUBSTITUTED AMINO)-2- PROPENOATE | ROHM & HAAS CO | 2000-05-23 | — | — | JP | disclosed |
| EP-1000926-A1 | Process for making 2-(trihaloacetyl)-3-(substituted aminos)-2-propenoates | ROHM AND HAAS COMPANY (US) | 2000-05-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110009642-A1 | Method for the Regioselective Synthesis of 1-Alkyl-3-haloalkyl-pyrazole-4-carboxylic Acid Derivatives | ATL3, HCAR3, AADAC | CYP2C9 422/4885NPSR1 2992/4885GLO1 1936/4885 |
| US-20250243190-A1 | NEW DEUTERATED RORGAMMA/RORGAMMAT INVERSE AGONISTS | RORB, RORA, RORC | CYP2C9 2000/4885NPSR1 161/4885GLO1 4699/4885 |
| US-20040147561-A1 | Pyrid-2-one derivatives and methods of use | PLPBP, PNPO, PDXK | CYP2C9 344/4885NPSR1 3531/4885GLO1 921/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.